Sinecatechins

Identification

Name
Sinecatechins
Accession Number
DB01266
Description

Sinecatechins is a botanical drug product for topical use. It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components. Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin (EGC), Epicatechin gallate (ECg) and some additional minor catechin derivatives i.e. Gallocatechin gallate (GCg), Gallocatechin (GC), Catechin gallate (Cg), and Catechin (C). In addition to the known catechin components, it also contains gallic acid, caffeine, and theobromine which together constitute about 2.5% of the drug substance. The remaining amount of the drug substance contains undefined botanical constituents derived from green tea leaves.

Type
Small Molecule
Groups
Approved, Investigational, Nutraceutical
Synonyms
  • Kunecatechins
  • Sinecatechins

Pharmacology

Indication

For the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

The mode of action of Sinecatechins (as ointment) involved in the clearance of genital and perianal warts is unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.

Mechanism of action

While the exact mechanism of action of catechins is unknown, they are powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
VeregenOintment10 %TopicalPaladin Labs Inc2014-07-04Not applicableCanada flag
VeregenOintment150 mg/1gTopicalPharmaDerm a division of Fougera Pharmaceuticals Inc.2007-12-14Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
D06BB12 — Sinecatechins
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
T432289GYZ
CAS number
188265-33-0
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
PubChem Substance
46506183
RxNav
753346
PharmGKB
PA164749508
Wikipedia
Sinecatechins
AHFS Codes
  • 84:04.06 — Antivirals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPerianal Warts / Wart, Genital1
4CompletedTreatmentVerruca, Warts1
3Not Yet RecruitingTreatmentHigh-grade Anal Intraepithelial Neoplasia1
3Unknown StatusTreatmentLamellar Ichthyosis1
2Not Yet RecruitingPreventionProstate Cancer1
2RecruitingTreatmentArousal Disorders, Sexual / Female Sexual Arousal Disorder / Female Sexual Dysfunction (FSD) / Genito-Pelvic Pain/Penetration Disorder / Painful Intercourse / Postmenopausal Syndrome / Sexual Pain Disorders / Vestibulodynia / Vulvodynia / Vulvovaginal Atrophy1
2, 3CompletedTreatmentBasal Cell Carcinoma (BCC)1
1CompletedTreatmentExternal Genital Warts1
Not AvailableCompletedTreatmentExternal Genital Warts1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Doak Dermatologics
Dosage Forms
FormRouteStrength
OintmentCutaneous10 %
OintmentTopical10 %
OintmentTopical150 mg/1g
Prices
Unit descriptionCostUnit
Veregen 15% ointment19.86USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5795911No1998-08-182020-10-31US flag
US5968973No1999-10-192017-04-10US flag
US7858662No2010-12-282026-10-02US flag
US9770406No2017-09-262025-07-12US flag
US10434059No2019-10-082022-11-18US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 16, 2007 14:06 / Updated on November 25, 2020 08:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates